Edition:
United Kingdom

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

199.38USD
15 Jan 2019
Change (% chg)

-- (--)
Prev Close
$199.38
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,323,011
52-wk High
$210.18
52-wk Low
$163.31

Select another date:

Mon, Jan 7 2019

Photo

U.S. top court rejects Amgen over cholesterol medication patent fight

WASHINGTON Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial.

UPDATE 4-U.S. top court rejects Amgen over cholesterol medication patent fight

WASHINGTON, Jan 7 Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial.

U.S. Supreme Court rejects Amgen over cholesterol medication patent fight

WASHINGTON, Jan 7 The U.S. Supreme Court on Monday declined to take up Amgen Inc's bid to reinstate a jury verdict it won against rivals Regeneron Pharmaceuticals Inc and Sanofi SA in patent dispute over cholesterol medication.

Teva, Amgen end dispute over generic Cinacalcet HCl tablets

Teva Pharmaceutical Industries Ltd said on Thursday it will pay an undisclosed amount to settle an ongoing dispute with Amgen Inc over its generic Cinacalcet HCl product.

Teva, Amgen end dispute over generic Cinacalcet HCl tablets

Jan 2 Teva Pharmaceutical Industries Ltd said on Thursday it will pay an undisclosed amount to settle an ongoing dispute with Amgen Inc over its generic Cinacalcet HCl product.

CORRECTED-BRIEF-Teva And Amgen Resolve Ongoing Dispute Over Teva's Generic Cinacalcet HCl Product

* TEVA AND AMGEN RESOLVE ONGOING DISPUTE OVER TEVA'S GENERIC CINACALCET HCL PRODUCT

Molecular Partners agrees cancer immunotherapy deal with Amgen

ZURICH Swiss biotechnology company Molecular Partners said it could earn more than $500 million (395 million pounds) in payments after striking a deal with U.S. drug giant Amgen to work together in cancer immunotherapy.

Molecular Partners agrees cancer immunotherapy deal with Amgen

ZURICH Swiss biotechnology company Molecular Partners said it could earn more than $500 million in payments after striking a deal with U.S. drug giant Amgen to work together in cancer immunotherapy.

Molecular Partners agrees cancer immunotherapy deal with Amgen

ZURICH, Dec 19 Swiss biotechnology company Molecular Partners said it could earn more than $500 million in payments after striking a deal with U.S. drug giant Amgen to work together in cancer immunotherapy.

Amgen antibody shows promise in myeloma trial, gets FDA fast track

SAN DIEGO Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.

Select another date: